CA2473815A1 - Aerosol formulation for inhalation containing a tiotropium salt - Google Patents
Aerosol formulation for inhalation containing a tiotropium salt Download PDFInfo
- Publication number
- CA2473815A1 CA2473815A1 CA002473815A CA2473815A CA2473815A1 CA 2473815 A1 CA2473815 A1 CA 2473815A1 CA 002473815 A CA002473815 A CA 002473815A CA 2473815 A CA2473815 A CA 2473815A CA 2473815 A1 CA2473815 A1 CA 2473815A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical preparation
- formulation
- preparation according
- tiotropium
- inhaler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nozzles (AREA)
Abstract
The present invention relates to a propellant-free aerosol formulation of a pharmaceutically acceptable salt of tiotropium dissolved in water. The formulation according to the invention is particularly suitable for nebulising the active substance using an atomiser in order to administer the active substance preferably to treat the indications asthma and COPD by inhalation.
Claims (28)
1. Pharmaceutical preparation consisting of .cndot. one or more tiotropium salt(s) as active substance, in a concentration based on tiotropium of between 0.01 g per 100 ml of formulation and 0.06 g per 100 ml of formulation, the tiotropium salt(s) being present in the pharmaceutical preparation in totally dissolved form .cndot. water as the only solvent, .cndot. acid for adjusting the pH to between 2.7 and 3.1, preferably 2.8 and 3.05, .cndot. a pharmacologically acceptable preservative, .cndot. a pharmacologically acceptable complexing agent and/or stabiliser and/or optionally one or more other pharmacologically acceptable excipients and additives.
2. Pharmaceutical preparation according to claim 1, characterised in that the tiotropium salt is a salt with HBr, HCl, HI, monomethyl sulphate, methanesulphonic acid and/or p-toluenesulphonic acid.
3. Pharmaceutical preparation according to claim 1, characterised in that the active substance is tiotropium bromide on its own.
4. Pharmaceutical preparation according to claim 1, characterised in that the active substance is tiotropium bromide monohydrate on its own.
5. Pharmaceutical preparation according to one of claims 1 to 4, characterised in that editic acid or a pharmacologically acceptable salt thereof is used as complexing agent.
6. Pharmaceutical preparation according to one of claims 1 to 4, characterised in that sodium edetate is used as the complexing agent.
7. Pharmaceutical preparation according to claim 6, characterised in that sodium edetate is present in an amount of between 5 mg / 100 ml of formulation and 20 mg / 100 ml of formulation, preferably between 8 mg / 100 ml of formulation and 12 mg / 100 ml of formulation.
8. Pharmaceutical preparation according to one of claims 1 to 7, characterised in that the pH is between 2.8 and 3.0, preferably 2.9.
9. Pharmaceutical preparation according to one of claims 1 to 7, characterised in that the pH is adjusted with an inorganic acid, preferably hydrochloric acid.
10. Pharmaceutical preparation according to one of claims 1 to 9, characterised in that the concentration based on tiotropium is between 0.02 g / 100 ml of formulation up to 0.05 g / 100 ml of formulation, preferably between 0.023 ~ 0.001 g per 100 ml of formulation up to 0.045 ~ 0.001g per 100 ml of formulation.
11. Pharmaceutical preparation according to one of claims 1 to 10, characterised in that the preparation contains benzalkonium chloride as preservative.
12. Pharmaceutical preparation according to one of claims 1 to 11, characterised in that the formulation does not contain any excipients and additives apart from water, the tiotropium salt, benzalkonium chloride, sodium edetate, hydrochloric acid and optionally sodium chloride.
13. Pharmaceutical preparation according to one of claims 1 to 12, characterised in that 100 ml of the formulation are prepared by dissolving 0.057 g of tiotropium bromide monohydrate, 10 mg of anhydrous benzalkonium chloride, 10 mg of sodium edetate in water ad 100 ml and sufficient 1 N hydrochloric acid to adjust the pH to 2.9.
14. Pharmaceutical preparation according to one of claims 1 to 12, characterised in that 100 ml of the formulation are prepared by dissolving 0.028 g of tiotropium bromide monohydrate, 10 mg of anhydrous benzalkonium chloride, 10 mg of sodium edetate in water ad 100 ml and sufficient 1N hydrochloric acid to adjust the pH to 2.9.
15. Pharmaceutical preparation according to one of claims 1 to 12, characterised in that 100 ml of the formulation are prepared by dissolving the tiotropium salt in an amount of 0.045 g based on tiotropium, 10 mg of anhydrous benzalkonium chloride, mg of sodium edetate in water ad 100 ml and sufficient 1N hydrochloric acid to adjust the pH to 2.9.
16. Pharmaceutical preparation according to one of claims 1 to 12, characterised in that 100 ml of the formulation are prepared by dissolving the tiotropium salt in an amount of 0.023 g based on tiotropium, 10 mg of anhydrous benzalkonium chloride, 10 mg of sodium edetate in water ad 100 ml and sufficient 1N hydrochloric acid to adjust the pH to 2.9.
17. Pharmaceutical preparation according to one of claims 1 to 16 for use as a medicament to be administered by inhalation.
18. Use of a pharmaceutical preparation according to one of claims 1 to 17 for nebulising in an inhaler according to WO 91/14468 or an inhaler as described in Figures 6a and 6b of WO 97/12687.
19. Use of a pharmaceutical preparation according to one of claims 1 to 17 for nebulising in an inhaler which nebulises defined amounts of the pharmaceutical formulation by the application of pressures of 100 to 600 bar through a nozzle with at least one nozzle opening 2 to 10 microns deep and 5 to 15 microns wide to produce an inhalable aerosol.
20 20. Use according to claim 19, characterised in that the minimum of one nozzle opening is at least two nozzle openings which are inclined at an angle of 20 to 160 °
to one another in the direction of the nozzle opening.
to one another in the direction of the nozzle opening.
21. Use according to claim 19 or 20, characterised in that the defined amounts are to 50 microlitres.
22. Use according to one of claims 19 to 21, characterised in that the inhaler is from 9 to 15 cm long and 2 to 4 cm wide.
23. Use according to one of claims 19 to 22, characterised in that the mass of formulation delivered, in at least 97% of all actuations of the inhaler, is between 5 and 30 mg, with a tolerance range of 25%.
24. Use according to claim 23, characterised in that the mass of formulation delivered, in at least 97% of all actuations of the inhaler, is between 5 and 30 mg, with a tolerance range of 20%.
25. Use according to one of claims 23 and 24, characterised in that the mass delivered is achieved in at least 98% of all actuations of the inhaler.
26. Use of a pharmaceutical preparation according to one of claims 1 to 17 as a medicament, particularly for treating asthma and/or COPD.
27. Method of treating asthma and/or COPD using a pharmaceutical preparation according to one of claims 1 to 17, particularly in an inhaler according to one of claims 18 to 25.
28. Process for preparing a pharmaceutical preparation according to one of claims 1 to 17 by mixing the individual components together.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10216036.8 | 2002-04-11 | ||
| DE10216036A DE10216036A1 (en) | 2002-04-11 | 2002-04-11 | Aerosol formulation for inhalation containing a tiotropium salt |
| PCT/EP2003/003438 WO2003084519A2 (en) | 2002-04-11 | 2003-04-02 | Aerosol formulation for inhalation comprising a tiotropium salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2473815A1 true CA2473815A1 (en) | 2003-10-16 |
| CA2473815C CA2473815C (en) | 2011-06-14 |
Family
ID=28458728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2473815A Expired - Fee Related CA2473815C (en) | 2002-04-11 | 2003-04-02 | Aerosol formulation for inhalation containing a tiotropium salt |
Country Status (33)
| Country | Link |
|---|---|
| EP (2) | EP1949892A1 (en) |
| JP (1) | JP2005531528A (en) |
| KR (1) | KR100997219B1 (en) |
| CN (1) | CN1309378C (en) |
| AR (1) | AR039286A1 (en) |
| AT (1) | ATE389391T1 (en) |
| AU (1) | AU2003222791B2 (en) |
| BR (1) | BR0309080A (en) |
| CA (1) | CA2473815C (en) |
| CO (1) | CO5611150A2 (en) |
| CY (1) | CY1108133T1 (en) |
| DE (2) | DE10216036A1 (en) |
| DK (1) | DK1496876T3 (en) |
| EA (1) | EA007228B1 (en) |
| EC (1) | ECSP045358A (en) |
| ES (1) | ES2303897T3 (en) |
| HK (1) | HK1078793A1 (en) |
| HR (1) | HRP20040932B1 (en) |
| ME (1) | ME00359B (en) |
| MX (1) | MXPA04009818A (en) |
| MY (1) | MY137249A (en) |
| NO (1) | NO334915B1 (en) |
| PE (1) | PE20030970A1 (en) |
| PL (1) | PL371204A1 (en) |
| PT (1) | PT1496876E (en) |
| RS (1) | RS50923B (en) |
| SA (1) | SA03240192B1 (en) |
| SI (1) | SI1496876T1 (en) |
| TW (1) | TWI344851B (en) |
| UA (1) | UA78994C2 (en) |
| UY (1) | UY27754A1 (en) |
| WO (1) | WO2003084519A2 (en) |
| ZA (1) | ZA200405721B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015065219A1 (en) * | 2013-10-28 | 2015-05-07 | Шолекс Девелопмент Гмбх | Ipratropium bromide solution |
| WO2015065223A1 (en) * | 2013-10-28 | 2015-05-07 | Шолекс Девелопмент Гмбх | Stable solution of fenoterol hydrobromide |
| EP1940349B1 (en) | 2005-10-10 | 2018-02-14 | Boehringer Ingelheim International GmbH | Aerosol formulation for the inhalation of beta agonists |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1682541T1 (en) | 2003-11-03 | 2010-06-30 | Boehringer Ingelheim Int | Method for producing tiotropium salts |
| AU2006277968A1 (en) * | 2005-08-06 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Use of tiotropium salts in the treatment of severe persistant asthma |
| EP1905440A1 (en) * | 2006-09-06 | 2008-04-02 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of a pharmaceutical composition comprising an anticholinergic for killing microorganisms and for treating respiratory tract infections |
| EP2044967A1 (en) * | 2007-10-01 | 2009-04-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Atomiser |
| WO2013127738A1 (en) | 2012-02-28 | 2013-09-06 | Boehringer Ingelheim International Gmbh | Novel propellant-gas-containing tiotropium formulation |
| RU2493827C1 (en) * | 2012-10-03 | 2013-09-27 | Шолекс Девелопмент Гмбх | Stable combined solution of fenoterol hydrobromide and ipratropium bromide |
| GB201507686D0 (en) * | 2015-05-05 | 2015-06-17 | Norton Healthcare Ltd | A stable tiotropium nebuliser solution |
| MX2019005563A (en) * | 2016-11-16 | 2019-08-12 | Glenmark Specialty Sa | Nebulized tiotropium. |
| WO2021188809A1 (en) * | 2020-03-19 | 2021-09-23 | Cai Gu Huang | Inhalable formulation of a solution containing levalbuterol tartrate |
| CN114259481A (en) * | 2021-11-26 | 2022-04-01 | 南京华盖制药有限公司 | Compound inhalation solution of odaterol |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3931041C2 (en) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| IL107120A (en) | 1992-09-29 | 1997-09-30 | Boehringer Ingelheim Int | Atomising nozzle and filter and spray generating device |
| DE19536903C2 (en) | 1995-10-04 | 1998-09-10 | Boehringer Ingelheim Int | Device for holding a fluidic component |
| DE19536902A1 (en) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Miniature fluid pressure generating device |
| DE19545226C1 (en) | 1995-12-05 | 1997-06-19 | Boehringer Ingelheim Int | Locking mechanism for a spring-operated output |
| DE19653969A1 (en) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | New aqueous pharmaceutical preparation for the production of propellant-free aerosols |
| DE19742439C1 (en) | 1997-09-26 | 1998-10-22 | Boehringer Ingelheim Int | Fluid micro-filter |
| DE19847968A1 (en) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit. |
| CN100396285C (en) * | 2000-10-31 | 2008-06-25 | 贝林格尔英格海姆法玛两合公司 | Inhalative solution formulation containing tiotropium salt |
-
2002
- 2002-04-11 DE DE10216036A patent/DE10216036A1/en not_active Withdrawn
-
2003
- 2003-02-04 UA UA20041109194A patent/UA78994C2/en unknown
- 2003-04-02 RS YUP-879/04A patent/RS50923B/en unknown
- 2003-04-02 MX MXPA04009818A patent/MXPA04009818A/en active IP Right Grant
- 2003-04-02 EP EP08152138A patent/EP1949892A1/en not_active Withdrawn
- 2003-04-02 ES ES03718724T patent/ES2303897T3/en not_active Expired - Lifetime
- 2003-04-02 CN CNB038082330A patent/CN1309378C/en not_active Ceased
- 2003-04-02 ME MEP-2008-543A patent/ME00359B/en unknown
- 2003-04-02 DK DK03718724T patent/DK1496876T3/en active
- 2003-04-02 BR BR0309080-9A patent/BR0309080A/en active Pending
- 2003-04-02 AT AT03718724T patent/ATE389391T1/en active
- 2003-04-02 JP JP2003581759A patent/JP2005531528A/en active Pending
- 2003-04-02 PL PL03371204A patent/PL371204A1/en not_active Application Discontinuation
- 2003-04-02 EP EP03718724A patent/EP1496876B1/en not_active Expired - Lifetime
- 2003-04-02 SI SI200331206T patent/SI1496876T1/en unknown
- 2003-04-02 WO PCT/EP2003/003438 patent/WO2003084519A2/en active IP Right Grant
- 2003-04-02 CA CA2473815A patent/CA2473815C/en not_active Expired - Fee Related
- 2003-04-02 AU AU2003222791A patent/AU2003222791B2/en not_active Expired
- 2003-04-02 PT PT03718724T patent/PT1496876E/en unknown
- 2003-04-02 EA EA200401305A patent/EA007228B1/en not_active IP Right Cessation
- 2003-04-02 KR KR1020047016052A patent/KR100997219B1/en active IP Right Grant
- 2003-04-02 DE DE50309414T patent/DE50309414D1/en not_active Expired - Lifetime
- 2003-04-09 UY UY27754A patent/UY27754A1/en not_active Application Discontinuation
- 2003-04-09 MY MYPI20031314A patent/MY137249A/en unknown
- 2003-04-09 PE PE2003000359A patent/PE20030970A1/en not_active Application Discontinuation
- 2003-04-10 TW TW092108240A patent/TWI344851B/en not_active IP Right Cessation
- 2003-04-11 AR ARP030101267A patent/AR039286A1/en active Pending
- 2003-07-07 SA SA03240192A patent/SA03240192B1/en unknown
-
2004
- 2004-07-19 ZA ZA200405721A patent/ZA200405721B/en unknown
- 2004-09-23 NO NO20044001A patent/NO334915B1/en not_active IP Right Cessation
- 2004-10-07 HR HRP20040932AA patent/HRP20040932B1/en not_active IP Right Cessation
- 2004-10-08 CO CO04100971A patent/CO5611150A2/en active IP Right Grant
- 2004-10-11 EC EC2004005358A patent/ECSP045358A/en unknown
-
2005
- 2005-12-01 HK HK05110950A patent/HK1078793A1/en not_active IP Right Cessation
-
2008
- 2008-06-11 CY CY20081100623T patent/CY1108133T1/en unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1940349B1 (en) | 2005-10-10 | 2018-02-14 | Boehringer Ingelheim International GmbH | Aerosol formulation for the inhalation of beta agonists |
| WO2015065219A1 (en) * | 2013-10-28 | 2015-05-07 | Шолекс Девелопмент Гмбх | Ipratropium bromide solution |
| WO2015065223A1 (en) * | 2013-10-28 | 2015-05-07 | Шолекс Девелопмент Гмбх | Stable solution of fenoterol hydrobromide |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1915129B1 (en) | Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation | |
| US6455524B1 (en) | Medicament compositions based on anticholinergically-effective compounds and beta-mimetics | |
| AU2003291497B2 (en) | The use of an anti-allergy agent and a steroid to treat allergic rhinitis | |
| US6677346B1 (en) | Methods comprising intranasal morphine | |
| CA2473815A1 (en) | Aerosol formulation for inhalation containing a tiotropium salt | |
| EP1782816B1 (en) | Water-based medicinal composition containing azithromycin and method of preparing the same | |
| WO2002094273A3 (en) | Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways | |
| SK4942001A3 (en) | Storable active substance concentrate with formoterol | |
| CN110237260A (en) | Pharmaceutical composition comprising R (+) budesonide and one or more bronchodilators | |
| JP2008513444A (en) | Methods for targeted delivery of lidocaine and other local anesthetics and treatment of cough and cough attacks | |
| JP2006506345A5 (en) | ||
| US7332175B2 (en) | Long-acting drug combinations for the treatment of respiratory complaints | |
| WO2021211858A8 (en) | Inhalable formulation of a solution containing tiotropium bromide and olodaterol | |
| AU2017312811A1 (en) | Liquid naloxone spray | |
| US20220331289A1 (en) | Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery | |
| CA2498727C (en) | Method for improving the ability of patients suffering from lung diseases to participate in and benefit from pulmonary rehabilitation programs | |
| CA2519679C (en) | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases | |
| US20150034087A1 (en) | Low Dose Pharmaceutical Composition Comprising Zanamivir | |
| JP2007522223A (en) | Controlled release formulation | |
| KR20140003504A (en) | Liquid propellant-free formulation comprising an antimuscarinic drug | |
| JP2005531528A5 (en) | ||
| US20160136089A1 (en) | Unit dose formulations of ketorolac for intranasal administration | |
| US20230255956A1 (en) | Pharmaceutical formulations containing nalbuphine | |
| CA2650813A1 (en) | New long-acting drug combinations for the treatment of respiratory diseases | |
| CA2617897A1 (en) | Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |